This venture capital firm headquartered in Northern Europe, is currently deploying capital from a life science focused fund. The firm primarily invests in biotech and digital health companies based in the Nordic and Baltic regions. The firm participates from Pre-Seed through Series A rounds, typically writing initial checks ranging from €250,000 to €3 million. The firm is open to both leading and co-investing in financing rounds.
While the firm’s primary focus lies in biotech and digital health, the firm is also open to investing in medical devices and diagnostics. Within biotech, the firm supports companies from the preclinical stage through to Phase I, with Phase II generally considered the latest point of entry. The firm maintains a disease-agnostic approach and is more focused on platform potential and scientific merit than on specific indications.
In most investments, the firm will seek a board seat, or at minimum, observer rights, reflecting its active involvement and strategic engagement with portfolio companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment